Potencial anti leishmania de las Fosfolipasas A2 (PLA2) presentes en los venenos de serpientes de la familia Viperidae

Abstract

Leishmaniasis is an unattended tropical disease caused by intracellular parasites of the Leishmania genus, transmitted via bite of infected mosquitoes. Three patologies are reported due to Leishmaniasis: cutaneous, mucocutaneous and visceral, being the first two the most common in Latin America. The current treatment of choice is the administration of expensive drugs, generating toxicity and resistance in patients. For these reasons, phospholipase A2, present in the snake’s venom, from the iperidae family, has been evaluated as a therapeutic alternative. This bibliographical review collects data from studies dated from 2015 to 2022. These reports confirm the use of PLA2 present in the venom of viperids and demonstrates its pharmacological potential against Leishmania. The present report would be used as a baseline to support further experimental research focused on new pharmacological molecules with less toxicity, more effectivity and less cost for Leishmaniasis treatment.